Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy

References

• Brown TA, Di Nardo PA, Lehman CL, Campbell LA. Reliability of DSM-IV anxiety and mood disorders: implications for the classification of emotional disorders. J Abnorm Psychol. 2001;110(1):49–58.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Ed. Washington, DC: American Psychiatric Association; 1994.
   Google Scholar
• World Health Organization. The World Health Report 2002: Reducing RisksiPromoting Healthy Life. Geneva, Switzerland: World Health Organization; 2002.
   Google Scholar
• Robins LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Arch Gen Psychiatry. 1981;38(4):381–389.
   PubMed Web of Science ®Google Scholar
• Robins LN, Regier DA. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991.
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Third Edition: DSM-III. 1st ed. Washington, DC: American Psychiatric Association; 1980.
   Google Scholar
• Weissman MM, Livingston BM, Leaf PJ, Florio LP, Holzer CI. Affective disorders. In: Robins LN, Regier DA, editors. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991. p. 53–80.
   Google Scholar
• Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8–19.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996;(30):17–30.
   Google Scholar
• Hirschfeld RM, Keller MB, Panico S, et al. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA. 1997;277(4):333–340.
   PubMed Web of Science ®Google Scholar
• Regier DA, Hirschfeld RM, Goodwin FK, Burke JD Jr, Lazar JB, Judd LL. The NIMH Depression Awareness, Recognition, and Treatment Program: structure, aims, and scientific basis. Am J Psychiatry. 1988;145(11):1351–1357.
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA. National trends in the outpatient treatment of depression. JAMA. 2002;287(2):203–209.
   PubMed Web of Science ®Google Scholar
• Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys’ estimates. Arch Gen Psychiatry. 2002;59(2):115–123.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.
   PubMed Web of Science ®Google Scholar
• Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry. 1997;170:205–228.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lopez AD. The Global Burden of DiseaseiA comprehensive assessment of mortality and disability from diseasesiinjuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.
   Google Scholar
• Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med. 1998;4(11):1241–1243.
   PubMed Web of Science ®Google Scholar
• Murray CJ. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72(3):429–445.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for major depressive disorder in adults. Am J Psychiatry. 1993;150(4):1–26.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Wan GJ, Mallick R, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol. 2004;24(5):497–506.
   PubMed Web of Science ®Google Scholar
• Biggs JT, Spiker DG, Petit JM, Ziegler VE. Tricyclic antidepressant overdose: incidence of symptoms. JAMA. 1977;238(2):135–138.
   PubMed Web of Science ®Google Scholar
• Gardner DM, Shulman KI, Walker SE, Tailor SA. The making of a user friendly MAOI diet. J Clin Psychiatry. 1996;57(3):99–104.
   PubMed Web of Science ®Google Scholar
• Gaudiano BA, Young D, Chelminski I, Zimmerman M. Depressive symptom profiles and severity patterns in outpatients with psychotic vs nonpsychotic major depression. Compr Psychiatry. 2008;49(5): 421–429.
   PubMed Web of Science ®Google Scholar
• Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355(9207):911–918.
   PubMed Web of Science ®Google Scholar
• Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994;8(4):238–249.
   PubMed Web of Science ®Google Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58(1):19–36.
   PubMed Web of Science ®Google Scholar
• Ferguson J, Cunningham L, Merideth C, et al. Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry. 1994;6(3):153–160.
   PubMedGoogle Scholar
• Stern WC, Harto-Truax N, Bauer N. Efficacy of bupropion in tricyclic-resistant or intolerant patients. J Clin Psychiatry. 1983;44 (5 Pt 2):148–152.
   PubMed Web of Science ®Google Scholar
• Conway CR, McGuire JM, Baram VY. Nefazodone-induced liver failure. J Clin Psychopharmacol. 2004;24(3):353–354.
   PubMed Web of Science ®Google Scholar
• Lipman AG. Analgesic drugs for neuropathic and sympathetically maintained pain. Clin Geriatr Med. 1996;12(3):501–515.
   PubMed Web of Science ®Google Scholar
• Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2005;3:CD005454.
   PubMedGoogle Scholar
• Bradley RH, Barkin RL, Jerome J, DeYoung K, Dodge CW. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther. 2003;10(5):318–323.
   PubMedGoogle Scholar
• Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60(8):1284–1289.
   PubMed Web of Science ®Google Scholar
• Krebs EE, Gaynes BN, Gartlehner G, et al. Treating the physical symptoms of depression with second-generation antidepressants: a systematic review and metaanalysis. Psychosomatics. 2008;49(3): 191–198.
   PubMed Web of Science ®Google Scholar
• Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983;16(1):87–101.
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, Manley AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007;68(5):677–688.
   PubMed Web of Science ®Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007;22(6):338–347.
   PubMed Web of Science ®Google Scholar
• Lieberman DZ, Montgomery SA, Tourian KA, et al. A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol. 2008;23(4):188–197.
   PubMed Web of Science ®Google Scholar
• Bao Y, Sturm R, Croghan TW. A national study of the effect of chronic pain on the use of health care by depressed persons. Psychiatr Serv. 2003;54(5):693–697.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.
   PubMed Web of Science ®Google Scholar
• Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: An emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1019–1027.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18(13):911–932.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000;157(9):1423–1428.
   PubMed Web of Science ®Google Scholar
• Hyman S, Nestler E. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry. 1996;153(2):151–162.
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008;23(5):243–253.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008;24(7):1877–1890.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Yeung PP, Entsuah R. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry. 2007;68(11): 1663–1672.
   PubMed Web of Science ®Google Scholar
• Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother. 2005;39(11):1798–1807.
   PubMed Web of Science ®Google Scholar
• Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology. 2003;28(3):552–557.
   PubMed Web of Science ®Google Scholar
• Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006;67(Suppl 4):14–21.
   PubMed Web of Science ®Google Scholar
• Sir A, D’Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005;66(10):1312–1320.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50(1):57–64.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77–87.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebocontrolled comparison with paroxetine. J Clin Psychopharmacol. 2004;24(4):389–399.
   PubMed Web of Science ®Google Scholar
• Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840–1847.
   PubMed Web of Science ®Google Scholar
• Priest RG. Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients. Clin Ther. 1996;18(2):347–358; discussion 302.
   PubMed Web of Science ®Google Scholar
• Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health. 2001;4(1):16–31.
   PubMedGoogle Scholar
• Einarson TR, Addis A, Iskedjian M. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics. 1997;12(2 Pt 2):286–296.
   PubMed Web of Science ®Google Scholar
• Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics. 2004;22(5):311–319.
   PubMed Web of Science ®Google Scholar
• Malone DC. A budget-impact and cost-effectiveness model for second-line treatment of major depression. J Manag Care Pharm. 2007;13(6 Suppl A):S8–S18.
   Web of Science ®Google Scholar
• Monfared AA, Han D, Sheehy O, Bexton B, Lelorier J. Assessment of Canadian provincial expenditures in depressed patients treated with venlafaxine XR versus SSRIs: the APEX Study. Curr Med Res Opin. 2006;22(1):83–94.
   PubMed Web of Science ®Google Scholar
• Morrow TJ. The pharmacoeconomics of venlafaxine in depression. Am J Manag Care. 2001;7(11 Suppl):S386–S392.
   Web of Science ®Google Scholar
• Woods SW. Pharmacoeconomic studies of antidepressants: focus on venlafaxine. Depress Anxiety. 2000;12(Suppl 1):102–109.
   PubMedGoogle Scholar
• Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther. 2005;27(1): 111–124.
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics. 2005;23(2):155–167.
   PubMed Web of Science ®Google Scholar
• Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs venlafaxine extended-release formulation. Int J Clin Pract. 2007;61(4):702–710.
   PubMed Web of Science ®Google Scholar
• Sorensen J, Stage KB, Damsbo N, Le Lay A, Hemels ME. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry. 2007;61(2):100–108.
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin. 2005;21(4):631–642.
   PubMed Web of Science ®Google Scholar
• Pristiq [package insert], Madison, NJ: Wyeth Pharmaceuticals; 2008.
   Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157(4 Suppl):1–45.
   Web of Science ®Google Scholar
• Nemeroff CB, Entsuah R, Benattia I, Demitrack M, Sloan DM, Thase ME. Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biol Psychiatry. 2008;63(4):424–434.
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007;62(11):1217–1227.
   PubMed Web of Science ®Google Scholar
• Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9(11):808–816, 818–821.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–1242.
   PubMed Web of Science ®Google Scholar
• Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol. 2007;10(1):51–61.
   PubMed Web of Science ®Google Scholar